Supplementary Material
Figure S1: Canertinib, afatinib and erlotinib decreases cell viability in pancreatic cancer cells. (A and B) Pancreatic cancer cell viability was assessed with indicated concentration of canertinib, afatinib and erlotinib for 24h using the MTT assay. More specifically, canertinib was tested at different concentrations such as 0, 0.5, 1, 2, and 5μM, afatinib at 0, 500 nM, 750 nM, 1μM, and 2μM and erlotinib at 0, 5, 20, and 40 μM. Our results demonstrate that treatment concentration of 0.5 μM concentration of canertinib had no effect on pancreatic cancer cell viability, whereas 1-5 μM concentration of canertinib led gradual decrease in cell viability in both CD18/HPAF and Capan-1 pancreatic cancer cells (98-56% and 86-49%, respectively). The effective concentration of 5 μM canertinib that inhibited cell viability by 50% was consider for further inhibitor (canertinib) studies in pancreatic cancer 
